Johnson & Johnson is topping profit and revenue expectations for the first quarter partially on strong sales of its psoriasis treatment, Stelara.
The New Brunswick, New Jersey, company on Tuesday posted profit of $3.75 billion, or $1.39 per share. Earnings, adjusted for amortization costs and research and development costs, were $2.10 per share, or 7 cents better that Wall Street expected, according to a survey by Zacks Investment Research.
Continue Reading Below
The world’s biggest maker of health care products posted revenue of $20.02 billion, also edging out projections.
_____
This story was generated by Automated Insights using data from Zacks Investment Research. Access a Zacks stock report on JNJ at https://www.zacks.com/ap/JNJ
